» Articles » PMID: 30366939

Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE)

Abstract

Purpose: The risk of subsequent breast cancer among female childhood cancer survivors is markedly elevated. We aimed to determine genetic contributions to this risk, focusing on polygenic determinants implicated in breast cancer susceptibility in the general population.

Experimental Design: Whole-genome sequencing (30×) was performed on survivors in the St Jude Lifetime Cohort, and germline mutations in breast cancer predisposition genes were classified for pathogenicity. A polygenic risk score (PRS) was constructed for each survivor using 170 established common risk variants. Relative rate (RR) and 95% confidence interval (95% CI) of subsequent breast cancer incidence were estimated using multivariable piecewise exponential regression.

Results: The analysis included 1,133 female survivors of European ancestry (median age at last follow-up = 35.4 years; range, 8.4-67.4), of whom 47 were diagnosed with one or more subsequent breast cancers (median age at subsequent breast cancer = 40.3 years; range, 24.5-53.0). Adjusting for attained age, age at primary diagnosis, chest irradiation, doses of alkylating agents and anthracyclines, and genotype eigenvectors, RRs for survivors with PRS in the highest versus lowest quintiles were 2.7 (95% CI, 1.0-7.3), 3.0 (95% CI, 1.1-8.1), and 2.4 (95% CI, 0.1-81.1) for all survivors and survivors with and without chest irradiation, respectively. Similar associations were observed after excluding carriers of pathogenic/likely pathogenic mutations in breast cancer predisposition genes. Notably, the PRS was associated with the subsequent breast cancer rate under the age of 45 years (RR = 3.2; 95% CI, 1.2-8.3).

Conclusions: Genetic profiles comprised of small-effect common variants and large-effect predisposing mutations can inform personalized breast cancer risk and surveillance/intervention in female childhood cancer survivors.

Citing Articles

Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.

Wang Z, Zhang J Nat Rev Cancer. 2024; 25(2):129-144.

PMID: 39511414 DOI: 10.1038/s41568-024-00768-6.


Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors.

Gibson T, Karyadi D, Hartley S, Arnold M, Berrington de Gonzalez A, Conces M Nat Med. 2024; 30(3):690-698.

PMID: 38454124 PMC: 11029534. DOI: 10.1038/s41591-024-02837-7.


Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first century.

Ehrhardt M, Krull K, Bhakta N, Liu Q, Yasui Y, Robison L Nat Rev Clin Oncol. 2023; 20(10):678-696.

PMID: 37488230 DOI: 10.1038/s41571-023-00802-w.


Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report.

Im C, Sharafeldin N, Yuan Y, Wang Z, Sapkota Y, Lu Z J Clin Oncol. 2023; 41(27):4381-4393.

PMID: 37459583 PMC: 10522108. DOI: 10.1200/JCO.23.00428.


Distinct DNA methylation signatures associated with blood lipids as exposures or outcomes among survivors of childhood cancer: a report from the St. Jude lifetime cohort.

Dong Q, Chen C, Song N, Qin N, Plonski N, Finch E Clin Epigenetics. 2023; 15(1):32.

PMID: 36855205 PMC: 9976538. DOI: 10.1186/s13148-023-01447-3.


References
1.
Henderson T, Moskowitz C, Chou J, Bradbury A, Neglia J, Dang C . Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2015; 34(9):910-8. PMC: 4871997. DOI: 10.1200/JCO.2015.62.3314. View

2.
Mavaddat N, Pharoah P, Michailidou K, Tyrer J, Brook M, Bolla M . Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015; 107(5). PMC: 4754625. DOI: 10.1093/jnci/djv036. View

3.
Kamihara J, Rana H, Garber J . Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat. 2014; 35(6):654-62. DOI: 10.1002/humu.22559. View

4.
Wang S, Qian F, Zheng Y, Ogundiran T, Ojengbede O, Zheng W . Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. Breast Cancer Res Treat. 2018; 168(3):703-712. PMC: 5916755. DOI: 10.1007/s10549-017-4638-1. View

5.
Easton D, Pharoah P, Antoniou A, Tischkowitz M, Tavtigian S, Nathanson K . Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015; 372(23):2243-57. PMC: 4610139. DOI: 10.1056/NEJMsr1501341. View